Edelman A S, Robinson M E, Sanchez P, Thorbecke G J
Department of Pathology, NYU School of Medicine, NY 10016.
Cell Immunol. 1987 Dec;110(2):321-37. doi: 10.1016/0008-8749(87)90126-2.
Immunity to a local (wing web) challenge with transplantable, chemically induced tumors, such as CHCT-NYU-4, can be transferred to histocompatible SC chickens with intravenously injected splenic T cells from tumor-immune chickens. Simultaneous iv injection of splenic T cells from chickens bearing progressively growing CHCT-NYU-4 prevents the expression of this adoptive systemic tumor immunity. The splenic suppressor T cells are B-L(Ia) positive and adhere to dishes coated with cimetidine-protein conjugate, suggesting that they bear type II histamine receptors (H2R). Intravenous injection of gamma-irradiated CHCT-NYU-4 cells 7 days prior to a local challenge with the same tumor promotes growth of a normally suboptimal tumor cell dose such that the incidence of progressive tumor growth is significantly increased. Concomitant treatment with the H2R antagonist, ranitidine, inhibits tumor growth of an optimal tumor dose challenge and promotes induction of tumor immunity. However, this drug cannot reverse the effect of iv injected tumor cells. Another drug with reported antisuppressor cell activity, cyclophosphamide (50 mg/kg), injected 1 day prior to challenge causes a transient inhibition of tumor growth. Injection of this drug on Day 7 does not have a significant effect by itself but, in combination with the Day-1 pretreatment, a significant inhibition of tumor growth by size and tumor incidence measurements is obtained. These results indicate that manipulation of immunity to transplantable fibrosarcomas in the chicken is possible with drugs acting on suppressor cells.
对可移植的化学诱导肿瘤(如CHCT-NYU-4)进行局部(翼蹼)攻击的免疫力,可以通过静脉注射来自肿瘤免疫鸡的脾T细胞,转移到组织相容性的SC鸡身上。同时静脉注射来自携带进行性生长的CHCT-NYU-4的鸡的脾T细胞,可阻止这种过继性全身肿瘤免疫力的表达。脾抑制性T细胞为B-L(Ia)阳性,并黏附于涂有西咪替丁-蛋白偶联物的培养皿上,这表明它们带有II型组胺受体(H2R)。在对同一肿瘤进行局部攻击前7天静脉注射经γ射线照射的CHCT-NYU-4细胞,可促进通常次优剂量肿瘤细胞的生长,从而使进行性肿瘤生长的发生率显著增加。用H2R拮抗剂雷尼替丁进行联合治疗,可抑制最佳肿瘤剂量攻击后的肿瘤生长,并促进肿瘤免疫力的诱导。然而,这种药物不能逆转静脉注射肿瘤细胞的作用。另一种据报道具有抗抑制细胞活性的药物环磷酰胺(50毫克/千克),在攻击前1天注射可引起肿瘤生长的短暂抑制。在第7天注射这种药物本身没有显著效果,但与第1天的预处理联合使用时,通过测量肿瘤大小和肿瘤发生率可获得对肿瘤生长的显著抑制。这些结果表明,使用作用于抑制细胞的药物来调控鸡对可移植纤维肉瘤的免疫力是可行的。